NEW YORK (GenomeWeb) – BG Medicine reported after the close of the market on Friday that its second quarter revenues plummeted 37 percent year over year as it narrowed its net loss.

For the three months ended June 30, the Waltham, Massachusetts-based firm reported total revenues of $505,000 compared to $799,000 in the year-ago period.

The company's Q2 net loss was $2.0 million, or $.23 per share, compared to a net loss of $2.2 million, or $.26 per share, in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.